Companies in the Materials sector have received a lot of coverage today as analysts weigh in on Dow (DOW), Lithium Americas (LAC) and MediPharm Labs (MEDIF).
Lithium Americas (LAC)
Canaccord Genuity analyst Reg Spencer maintained a Buy rating on Lithium Americas on February 9 and set a price target of C$11.50. The company’s shares closed last Tuesday at $13.79.
Spencer has an average return of 233.0% when recommending Lithium Americas.
According to TipRanks.com, Spencer is ranked #802 out of 6976 analysts.
Currently, the analyst consensus on Lithium Americas is a Moderate Buy with an average price target of $13.00, a -18.1% downside from current levels. In a report issued on August 18, National Bank also maintained a Buy rating on the stock with a $10.00 price target.
MediPharm Labs (MEDIF)
Canaccord Genuity analyst Kimberly Hedlin maintained a Buy rating on MediPharm Labs on February 10 and set a price target of C$6.75. The company’s shares closed last Tuesday at $0.70.
According to TipRanks.com, Hedlin is ranked #2551 out of 6976 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MediPharm Labs with a $1.44 average price target, implying a 94.0% upside from current levels. In a report issued on January 27, Roth Capital also maintained a Buy rating on the stock with a C$8.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MEDIF:
